Analysis of the clinical significance of DNA methylation in gastric cancer based on a genome-wide high-resolution array

Wen-Liang Fang1,2*, Ming-Huang Chen2,3, Kuo-Hung Huang1,2, Shih-Ching Chang2,4, Chien-Hsing Lin5, Yee Chao2,3, Su-Shun Lo2,6, Anna Fen-Yau Li2,7, Chew-Wun Wu1,2 and Yi-Ming Shyr1,2

Abstract

Background: Aberrant DNA methylation is involved in gastric carcinogenesis and may serve as a useful biomarker in the diagnosis and detection of gastric cancer (GC) recurrence.

Results: A total of 157 patients who received surgery for GC were enrolled in the present study. A genome-wide methylation analysis was performed in tumor and adjacent normal tissues for the discovery set of 16 GC patients; the top three hypermethylated CpG sites of DNA promoters were selected for validation in tissue and plasma samples for the validation set of 141 GC patients. The frequencies of the top three hypermethylated genes in available patient tissues (n = 141) and plasma samples (n = 106) were 41.8% and 38.7%, respectively, for ADAM19; 40.4% and 42.5%, respectively, for FLI1; and 56.7% and 50.9%, respectively, for MSC. In both tissue and plasma samples, FLI1 hypermethylation was associated with more advanced GC and liver and distant lymphatic metastasis, and ADAM19 hypermethylation was associated with more stage IV GC. In plasma samples, MSC hypermethylation was more common in non-superficial type GC than samples without MSC hypermethylation. In both tissue and plasma samples, patients with methylation of all the three genes had significantly more liver metastases, distant lymphatic metastases, and paraaortic lymph node metastases than patients with two or fewer hypermethylated genes. The survival analysis showed that only for stage III GC, patients with hypermethylation of two or three genes had a worse 5-year disease-free survival rate than those with hypermethylation of one or none of the three genes. Subgroup analysis showed that FLI1 hypermethylation in both tissue and plasma samples was associated with liver metastasis in MSI−/EBV− GC, and MSC hypermethylation in tissue samples was correlated with liver metastasis in MSI+ or EBV+ GC. Patients with FLI1 hypermethylation in plasma samples had a significantly worse 5-year disease-free survival rate than those without FLI1 hypermethylation in MSI−/EBV− GC. FLI1 hypermethylation was an independent prognostic factor affecting the overall survival and disease-free survival in both tissue and plasma samples.

Conclusions: DNA methylation is a useful biomarker for predicting tumor recurrence patterns and GC patient survival.

Keywords: Methylation, Plasma, Recurrence pattern, Distant metastasis, Survival
Background
Although the worldwide incidence of gastric cancer (GC) has been declining, it remains the sixth most common cancer and the second most common cause of cancer-related death [1]. Despite advances in diagnostic methods and treatment modalities, the prognosis of GC remains unsatisfactory because most patients are diagnosed at an advanced stage. To improve patient survival, useful biomarkers are needed to support the early diagnosis of GC and the early detection of cancer recurrence.

Even in early stage GC, aberrant DNA methylation may contribute to gastric carcinogenesis by silencing of tumor suppressor genes or stimulating the expression of oncogenes [2–4]. A meta-analysis found that several hypermethylated genes were differentially expressed between normal and GC tissues [5]. In addition to their usefulness in tumor tissues, some hypermethylated genes identified in plasma have been correlated with clinical significance in hepatocellular carcinoma (HOXA1, EMI1, AK055957, ECE1, PKP1, and CLEC11A), colorectal cancer (AGBL4, FLI1, and TWIST1), and GC (ELMO1, ZNF569, and CI3orf18) [6–8]. However, to date, genome-wide analyses aimed at identifying and validating novel hypermethylated genes in both tissue and plasma samples obtained from GC patients are lacking.

The Cancer Genome Atlas (TCGA) [9] classifies GC into four types: (1) Epstein-Barr virus positive (EBV+), (2) microsatellite instability-high (MSI+), (3) genomically stable, and (4) chromosomal instability. Most of the prognostic DNA methylation markers are hypermethylated in MSI+ and EBV+ GC, and the methylation status of these markers is likely to be associated with good prognosis [9–11]. Although there are several reports of DNA methylation markers associated with poor prognosis [12–16], they are rarely used in clinical practice. Most studies reporting these markers did not demonstrate validation analyses with independent samples and were not supported by subsequent studies by other investigators.

The aim of this study was to use genome-wide methylation analysis to identify novel hypermethylated genes that can discriminate tumors from normal tissues in GC patients. We further validated the top three hypermethylated genes in both tissue and plasma samples and investigated the correlations between hypermethylated genes and the clinicopathological characteristics and recurrence patterns of GC patients. Furthermore, the present study classified GC into subtypes according to MSI/EBV status. The methylation frequencies of the top three hypermethylated genes and their correlation with the clinicopathological characteristics and prognosis among the GC subtypes were compared.

Results
Clinicopathological characteristics
As shown in Fig. 1, genome-wide Illumina methylation EPIC BeadChip profiling was performed on tumor and adjacent normal DNA samples of the discovery set of 16 GC patients (including four patients in each TNM stage). We compared the methylation patterns between tumor and normal tissues and found that 2180 of 865,918 CpG sites (0.25%) were differentially methylated in the tumor tissues. These CpG sites were within or near 837 functional genes; 78.4% (1710 CpG sites) were hypermethylated, and 21.6% (470 CpG sites) were hypomethylated in the tumor group. EpiTect Control DNA (Qiagen) was used to assess the performance of the MassARRAY EpiTYPING method and primer design. The values of the methylation sites were 0.95 ± 0.09 and 0.02 ± 0.13 in the methylated and unmethylated controls, respectively, indicating that the primer designs were acceptable for this study. Additional file 1 showed the raw data of the results of genome-wide methylation profiling using an Illumina Methylation EPIC BeadChip assay. The data of the hypermethylated and hypomethylated genes that were significantly differentially expressed between the normal and cancer tissues are shown in Additional file 2.

To replicate the results from our genome-wide methylation analysis, we selected the top three hypermethylated CpG islands from the discovery set of 16 GC patients, including A Disintegrin and Metalloproteinase 19 (ADAM19), Friend Leukemia Integration 1 (FLI1), and Musculin (MSC, hg19 chr8:72,756,005-72,756,149) genes. Validation of the same CpG sites of the three genes was performed in 141 independent GC patients using a MALDI-TOF-based methylation profiling method. The ADAM19, FLI1, and MSC genes were hypermethylated in tumor tissues in 59 (41.8%), 57 (40.4%), and 80 cases (56.7%), respectively. The raw data of the clinical profile of the discovery set (n = 16) and validation set (n = 141) of GC patients was shown in Additional file 3 and Additional file 4. The clinical profile of the discovery set and validation set was shown in Additional file 5: Table S1. As shown in Additional file 4, the most frequently differentially hypomethylated CpG islands different between the normal and tumor tissues were TACSTD2, followed by SIM2 and DAPK1.

Tissue samples
As shown in Table 1, patients with ADAM19 hypermethylation more often had stage IV GC than those without ADAM19 hypermethylation (P = 0.043); patients with FLI1 hypomethylation had fewer early GC (pT1) than those without FLI1 hypermethylation (P = 0.003). No correlations were found between the clinicopathological characteristics and MSC hypermethylation in GC patient tissues. The correlations of the hypermethylation status of the three genes in tissue samples were shown in Additional file 6: Table S2 and Fig. 3a. Patients with ADAM19 hypermethylation were significantly associated with FLI1 hypermethylation. Patients
with FLI1 hypermethylation were significantly associated with MSC hypermethylation (Additional file 6: Table S2). Thirty-one patients had co-hypermethylation of ADAM19 and FLI1; 39 patients had co-hypermethylation of ADAM19 and MSC; 43 patients had co-hypermethylation of FLI1 and MSC; and 29 patients had co-hypermethylation of the three genes (Fig. 2a).

We further divided 141 GC patients into three groups according to the MSI/EBV status to analyze their correlation with methylated genes: MSI+/EBV− (n = 12), EBV+/MSI− (n = 26), and MSI−/EBV− (n = 99). Four patients with MSI+/EBV+ were excluded because the sample size was too small for analysis. As shown in Additional file 7: Table S3 and Fig. 3a, the frequency of ADAM19 hypermethylation was similar among the three groups, which was also observed for MSC hypermethylation. The frequency of FLI1 hypermethylation was the highest in the EBV+/MSI− group, followed by the MSI+/EBV− group and MSI−/EBV− group.

**Plasma samples**

To obtain a higher sensitivity, the methylation status of the above three genes in cell-free DNA (cfDNA) was evaluated using the NGS method in 106 patients. The concentration of cfDNA extracted from plasma was 1.513 ± 3.838 ng/ul. The average methylation values of the normal control group were 0.017, 0.008, and 0.052 for the ADAM19, FLI1, and MSC genes, respectively. The correlations of the
Table 1 Clinical profile in the tissue and plasma samples of gastric cancer patients with hypermethylation of the ADAM19, FLI1, and MSC genes

| Variables                              | Tissue samples |            | P value | Plasma samples |            | P value |            | P value |            | P value |            | P value |            | P value |
|----------------------------------------|----------------|------------|---------|----------------|------------|---------|------------|---------|------------|---------|------------|---------|------------|---------|
|                                        | Case no., n=141 | ADAM19 n=59 | FLI1 n=57 | MSC n=80       | Case no., n=106 | ADAM19 n=41 | FLI1 n=45 | MSC n=54 |            |         |           |         |           |         |
|                                        |                |            | P       |                |            | P       |            | P       |            |         |           | P       |            | P       |
| Age (years)                            | 0.597          | 0.860      | 0.860   | 0.537          | 0.860      | 0.686   |            |         |           |         |           |         |           |         |
| < 65/≧ 65                             | 51/90          | 23/36      | 20/37   | 28/52          | 38/68      | 13/28   | 15/30      | 18/36   |            |         |           |         |           |         |
| Gender                                 | 0.163          | 0.319      | 0.167   | 1.000          | 0.110      | 0.650   |            |         |           |         |           |         |           |         |
| Male/female                            | 107/34         | 41/18      | 46/11   | 57/23          | 81/25      | 31/10   | 38/7       | 40/14   |            |         |           |         |           |         |
| Tumor size (cm)                        | 0.247          | 0.847      | 0.848   | 0.827          | 0.830      | 0.832   |            |         |           |         |           |         |           |         |
| < 5/≧ 5                                | 36/105         | 12/47      | 14/43   | 21/59          | 31/75      | 11/30   | 14/31      | 15/39   |            |         |           |         |           |         |
| Cell differentiation                   | 0.814          | 0.666      | 0.221   | 0.843          | 0.434      | 0.119   |            |         |           |         |           |         |           |         |
| Poor/moderate/well                     | 71/69/1        | 30/29/0    | 27/30/0 | 37/42/1        | 50/56/0    | 20/21/0 | 19/26/0    | 21/33/0 |            |         |           |         |           |         |
| Gross appearance                       | 0.069          | 0.218      | 0.170   | 0.154          | 0.296      | 0.025   |            |         |           |         |           |         |           |         |
| Superficial type                       | 18             | 3 (17.6)   | 4 (22.2) | 7 (38.9)       | 12         | 0       | 3 (25.0)   | 2 (16.7) |            |         |           |         |           |         |
| Borrmann type 1 and 2                 | 30             | 15 (51.7)  | 14 (46.7) | 20 (66.7)     | 25         | 14 (56.0)| 13 (52.0)  | 16 (64.0) |            |         |           |         |           |         |
| Borrmann type 3 and 4                 | 93             | 34 (37.0)  | 39 (41.9) | 53 (57.0)     | 69         | 27 (39.1)| 29 (42.0)  | 36 (52.2) |            |         |           |         |           |         |
| Lauren's classification                | 0.718          | 1.000      | 0.591   | 0.667          | 1.000      | 0.591   |            |         |           |         |           |         |           |         |
| Intestinal/diffuse type                | 94/47          | 38/21      | 38/19   | 55/25          | 75/31      | 28/13   | 32/13      | 55/25   |            |         |           |         |           |         |
| Lymphovascular invasion                | 0.416          | 0.540      | 0.421   | 0.247          | 0.821      | 0.256   |            |         |           |         |           |         |           |         |
| Absent/present                         | 32/109         | 11/48      | 11/46   | 16/64          | 25/81      | 7/34    | 10/35      | 10/44   |            |         |           |         |           |         |
| Pathological T category                | 0.440          | 0.003      | 0.758   | 0.053          | 0.009      | 0.243   |            |         |           |         |           |         |           |         |
| T1                                     | 16             | 4 (25.0)   | 4 (25.0) | 8 (50.0)       | 12         | 1 (8.3) | 4 (33.3)   | 3 (25.0) |            |         |           |         |           |         |
| T2                                     | 23             | 9 (39.1)   | 17 (73.9) | 15 (65.2)     | 18         | 7 (38.9)| 14 (77.8)  | 10 (55.6) |            |         |           |         |           |         |
| T3                                     | 34             | 14 (41.2)  | 10 (29.4) | 18 (52.9)     | 29         | 12 (41.4)| 9 (51.0)   | 14 (48.3) |            |         |           |         |           |         |
| T4                                     | 68             | 32 (47.1)  | 26 (38.2) | 39 (57.4)     | 47         | 21 (44.7)| 18 (38.3)  | 27 (57.4) |            |         |           |         |           |         |
| Pathological N category                | 0.383          | 1.000      | 0.770   | 0.437          | 0.087      | 0.290   |            |         |           |         |           |         |           |         |
| N0                                     | 45             | 16 (35.6)  | 18 (40.0) | 24 (53.3)     | 36         | 12 (33.3)| 17 (47.2)  | 14 (38.3) |            |         |           |         |           |         |
| N1                                     | 25             | 12 (48.0)  | 10 (40.0) | 15 (60.0)     | 21         | 9 (42.9)| 8 (38.1)   | 12 (57.1) |            |         |           |         |           |         |
| N2                                     | 22             | 7 (31.8)   | 9 (40.9)  | 11 (50.0)     | 18         | 5 (27.8)| 8 (44.4)   | 9 (50.0)  |            |         |           |         |           |         |
| N3                                     | 49             | 24 (49.0)  | 20 (40.8) | 30 (61.2)     | 31         | 15 (48.4)| 12 (38.7)  | 19 (61.3) |            |         |           |         |           |         |
| Pathological TNM stage                 | 0.043          | 0.448      | 0.926   | 0.042          | 0.356      | 0.160   |            |         |           |         |           |         |           |         |
| I                                      | 26             | 8 (30.8)   | 11 (42.3) | 15 (57.7)     | 21         | 5 (23.8)| 11 (52.4)  | 8 (38.1)  |            |         |           |         |           |         |
| II                                     | 40             | 16 (40.0)  | 19 (47.5) | 22 (55.0)     | 32         | 13 (40.6)| 16 (50.0)  | 16 (50.0) |            |         |           |         |           |         |
| III                                    | 65             | 27 (41.5)  | 23 (35.4) | 38 (58.5)     | 48         | 18 (37.5)| 16 (33.3)  | 27 (56.3) |            |         |           |         |           |         |
| IV                                     | 10             | 8 (80.0)   | 4 (400)   | 5 (50.0)      | 5          | 5 (100) | 2 (40.0)   | 3 (60.0)  |            |         |           |         |           |         |
hypermethylation status of the three genes in plasma samples were shown in Additional file 8: Table S4 and Fig. 3b. Among these 106 patients, 41 (38.7%), 45 (42.5%), and 54 (50.9%) were found to exhibit genetic hypermethylation in cfDNA of the ADAM19, FLI1, and MSC genes, respectively. Patients with hypermethylation of any one of the three genes were significantly associated with hypermethylation of the other two genes (Additional file 9: Table S4). Twenty-three patients had co-hypermethylation of ADAM19 and FLI1; 31 patients had co-hypermethylation of ADAM19 and MSC; 31 patients had co-hypermethylation of FLI1 and MSC; and 22 patients had co-hypermethylation of the three genes (Fig. 2b). As shown in Table 1, patients with ADAM19 hypermethylation in cfDNA were more likely to have stage IV GC than those without ADAM19 hypermethylation. Patients with FLI1 hypermethylation in cfDNA had fewer early GCs (pT1) than those without FLI1 hypermethylation. Patients with MSC hypermethylation in cfDNA had fewer superficial-type GCs than those without MSC hypermethylation.

The 106 patients with plasma samples were divided into three groups: MSI+/ EBV− (n = 8), EBV+/ MSI− (n = 21), and MSI−/EBV− (n = 75). Two patients with MSI+/EBV+ were excluded. Similar to the findings in patients with tissue samples, the frequency of ADAM19 and MSC hypermethylation was not significantly different among the three groups. FLI1 hypermethylation was the highest in the EBV+/MSI− group, followed by the MSI+/EBV− group and MSI−/EBV− group (Additional file 7: Table S3, Fig. 3b).

---

Fig. 2 The correlations of the hypermethylation status of the three genes. a Tissue samples. b Plasma samples.

Fig. 3 The bar chart of the frequencies of the three methylated genes in different GC subtypes according to MSI/EBV status. a Tissue samples. b Plasma samples.
Initial recurrence patterns
Tissue samples
Among the 141 patients, 119 who received curative surgery were analyzed for the initial recurrence patterns. Patients with FLII hypermethylation in GC tissues were associated with more liver metastases (P = 0.026), more distant lymphatic metastases (P = 0.038), and more paraaortic lymph node metastases (P = 0.007) than those without FLII hypermethylation. Patients with MSC hypermethylation in GC tissues had more liver metastases than those without MSC hypermethylation (P = 0.012). No correlation was found between the initial recurrence pattern and ADAM19 hypermethylation in GC tissues (Table 2).

Regarding the number of hypermethylated genes, patients with hypermethylation of all three genes had significantly more liver metastases (P = 0.006), more distant lymphatic metastases (P = 0.009), and more paraaortic lymph node metastases (P = 0.009) than patients with hypermethylation of two or fewer of the three genes.

The 119 patients were divided into two groups: (MSI+ or EBV+) and MSI−/EBV−. Regarding ADAM19 hypermethylation, there was no significant difference in the initial recurrence patterns between patients with or without ADAM19 hypermethylation in either group. MSI−/EBV− patients with FLII hypermethylation were associated with more liver metastasis than those without FLII hypermethylation, while no significant difference in initial recurrence patterns was observed in MSI+ or EBV+ patients (Table 3). MSI+ or EBV+ patients with MSC hypermethylation were associated with more liver metastasis than those without MSC hypermethylation, while no significant difference in initial recurrence patterns was found in MSI−/EBV− patients (Table 3). Regarding the number of hypermethylated genes, MSI+ or EBV+ patients with at least two hypermethylated genes in the tissue samples were associated with more liver metastasis than those with less than two hypermethylated genes, which was not observed in MSI−/EBV− patients (Table 4).

Plasma samples
Among the 106 GC patients with available plasma samples, 93 patients receiving curative surgery were enrolled for the analysis of initial recurrence patterns. Patients with FLII hypermethylation in cfDNA had more liver metastases (P = 0.042) and more paraaortic lymph node metastases (P = 0.021) than those without FLII hypermethylation. No correlation was found between the initial recurrence pattern and the methylation status of ADAM19 or MSC in GC plasma samples (Table 2). Regarding the number of hypermethylated genes, patients with hypermethylation of all three genes had significantly more liver metastases (P = 0.029) and more paraaortic lymph node metastases (P = 0.037) than patients with hypermethylation of two or fewer of the three genes.

The 93 patients were divided into two groups according to MSI/EBV status: MSI+ or EBV+ group and MSI−/EBV− group. Regarding ADAM19 or MSC hypermethylation, there was no significant difference in the initial recurrence patterns in either group of patients. MSI−/EBV− patients with FLII hypermethylation in plasma samples were associated with more hematogenous metastasis and liver metastasis than those without FLII hypermethylation, which was not observed in MSI+ or EBV+ patients (Table 5). Regarding the number of hypermethylated genes in plasma samples, there was no significant difference in the initial recurrence patterns in both groups.

Survival analysis
Among the 119 patients who received curative surgery, the 5-year OS rates did not significantly differ between patients with one or no hypermethylated genes and patients with two or three hypermethylated genes (51.8% vs. 41.7%, P = 0.539). Among stage III GC patients, a trend of worse 5-year OS rates was observed for patients with two or three hypermethylated genes than for those with one or no hypermethylated genes (20.0% vs. 40.0%, P = 0.074).

The 5-year DFS rates did not significantly differ between patients with one or no hypermethylated genes and patients with two or three hypermethylated genes (47.0% vs. 36.1%, P = 0.240, Fig. 4a). In stage III GC patients, the 5-year DFS rates were significantly worse in patients with two or three hypermethylated genes than for those with one or no hypermethylated genes (20.0% vs. 34.3%, P = 0.039, Fig. 4b).

For subgroup analysis, MSI−/EBV− patients with FLII hypermethylation in plasma samples had a trend of worse 5-year OS rates (33.3% vs. 56.1%, P = 0.104) and a significantly worse 5-year DFS rates (29.2% vs. 53.7%, P = 0.033) than those without FLII hypermethylation, which was not observed in MSI+ or EBV+ GC. Furthermore, there was no significant difference in 5-year OS and DFS rates between patients with or without hypermethylation of ADAM19 or MSC in either (MSI+ or EBV+) GC patients or MSI−/EBV− GC patients.

As shown in Additional file 9: Table S5, in both tissue and plasma samples, multivariate analysis demonstrated that FLII hypermethylation, pathological TNM stage, and adjuvant chemotherapy were independent prognostic factors affecting OS. In both tissue and plasma samples, multivariate analysis showed that FLII hypermethylation, pathological TNM stage, adjuvant chemotherapy, and cell differentiation were independent prognostic factors affecting DFS.

Table 6 demonstrated the summary of the prognostic value of patients with hypermethylated genes compared with those without hypermethylated genes in tissue and plasma samples.
Table 2 The patterns of initial recurrence of gastric cancer after curative surgery according to the methylation status of the three genes in the tissue and plasma samples of gastric cancer patient

|                         | Tissue samples |                                   | Plasma samples |                                   |
|-------------------------|----------------|------------------------------------|----------------|------------------------------------|
|                         | Case no. n = 119 | ADAM19 n = 49                     | Case no. n = 93 | ADAM19 n = 36                     |
|                         | ADAM19 n = 49  | P value                            | P value        | P value                            |
|                         |                | FLI1 n = 49                        |                | FLI1 n = 42                        |
|                         |                | MSC n = 67                         |                | MSC n = 42                         |
| Total recurrence        | 55             | 21 (38.2) 0.0579                   | 44             | 18 (40.9) 0.831                    |
|                         |                | 27 (49.1) 0.135                    |                | 23 (52.3) 0.216                    |
|                         |                | 33 (60.0) 0.0465                   |                | 23 (52.3) 0.836                    |
| Locoregional recurrence | 22             | 11 (50.0) 0.0472                   | 17             | 9 (52.9) 0.242                     |
|                         |                | 11 (50.0) 0.0472                   |                | 10 (52.9) 0.230                    |
|                         |                | 15 (68.2) 0.0242                   |                | 11 (54.7) 0.284                    |
| Hepatoduodenal ligament | 10             | 5 (50.0) 0.0739                    | 6              | 3 (50.0) 0.674                     |
|                         |                | 5 (50.0) 0.0739                    |                | 4 (66.7) 0.404                     |
|                         |                | 6 (60.0) 1.000                     |                | 3 (50.0) 1.000                     |
| Abdominal wall          | 13             | 7 (53.8) 0.0378                    | 11             | 6 (54.5) 0.0327                    |
|                         |                | 7 (53.8) 0.0378                    |                | 7 (63.6) 0.214                     |
|                         |                | 10 (76.9) 0.144                    |                | 9 (81.8) 0.050                     |
| Perigastric area        | 1              | 1 (100) 0.0412                     | 1              | 1 (100) 0.0387                    |
|                         |                | 0                                  |                | 0                                  |
|                         |                | 1                                  |                | 1                                  |
| Anatomosis              | 11             | 4 (36.4) 1.000                     | 10             | 4 (400) 1.000                     |
|                         |                | 7 (63.6) 0.754                     |                | 6 (600) 0.339                     |
| Distant metastasis      | 42             | 16 (38.1) 0.0698                   | 32             | 13 (40.6) 0.825                    |
|                         |                | 20 (47.6) 0.333                    |                | 16 (500) 0.519                     |
|                         |                | 27 (64.3) 0.247                    |                | 17 (53.1) 0.828                    |
| Peritoneal dissemination | 16             | 6 (37.5) 0.0732                    | 13             | 5 (38.5) 1.000                    |
|                         |                | 6 (37.5) 0.0732                    |                | 5 (38.5) 0.766                     |
|                         |                | 9 (56.3) 1.000                     |                | 7 (53.8) 1.000                     |
| Hematogenous metastasis | 20             | 7 (35.0) 0.624                     | 14             | 6 (429) 0.771                     |
|                         |                | 11 (55.0) 0.215                    |                | 8 (57.1) 0.390                     |
| Liver                   | 12             | 5 (41.7) 1.000                     | 9              | 4 (444) 0.731                     |
|                         |                | 9 (75.0) 0.026                     |                | 7 (778) 0.042                     |
| Lung                    | 5              | 1 (20.0) 0.0648                    | 4              | 1 (250) 1.000                     |
|                         |                | 0                                  |                | 0                                  |
|                         |                | 2 (40.0) 0.0652                    |                | 0                                  |
| Bone                    | 6              | 1 (16.7) 0.399                     | 4              | 1 (250) 0.624                     |
|                         |                | 2 (33.3) 0.230                     |                | 2 (500) 1.000                     |
|                         |                | 10 (500) 0.017                     |                | 1 (500) 0.502                     |
| Distant lymphatic recurrence | 13     | 7 (53.8) 0.0378                    | 10             | 5 (500) 0.144                     |
| Virchow’s node          | 1              | 1 (100) 0.0412                    | 1              | 1 (100) 0.0387                    |
| Lymphangitis carcinomatosa | 2      | 1 (50.0) 1.000                     | 2              | 1 (500) 1.000                     |
| Para-aortic lymph node  | 11             | 6 (54.5) 0.357                     | 8              | 4 (500) 0.706                     |
|                         |                | 9 (81.8) 0.007                     |                | 7 (875) 0.021                     |
|                         |                | 8 (72.7) 0.344                     |                | 6 (75.0) 0.267                    |

Some patients had more than one initial recurrence patterns.
## Table 3

The initial recurrence patterns of gastric cancer patients receiving curative surgery with or without hypermethylation of FLI1 or MSC in tissue samples according to MSI/EBV status

| FLI1 hypermethylation | MSC hypermethylation | P value |
|------------------------|-----------------------|---------|
| Without n = 16 | With n = 21 | Without n = 16 | With n = 21 | P value |
| Total recurrence | 6 (37.5) | 11 (52.4) | 0.368 | 6 (37.5) | 11 (52.4) | 0.368 |
| Locoregional recurrence | 11 (204) | 8 (28.6) | 0.404 | 6 (167) | 13 (28.3) | 0.217 |
| Hepatoduodenal ligament | 1 (6.3) | 2 (9.5) | 0.245 | 5 (9.3) | 4 (14.3) | 0.490 |
| Abdominal wall | 2 (9.5) | 2 (9.5) | 0.204 | 5 (17.9) | 5 (17.9) | 0.395 |
| Perigastric area | 1 (19) | 0 | 0.469 | 1 (28) | 0 | 0.255 |
| Anastomosis | 1 (6.3) | 4 (19.0) | 0.259 | 2 (125) | 3 (14.3) | 0.875 |
| Distant metastasis | 5 (31.3) | 8 (38.1) | 0.666 | 3 (188) | 10 (47.6) | 0.068 |
| Peritoneal dissemination | 1 (6.3) | 3 (14.3) | 0.435 | 1 (6.3) | 3 (14.3) | 0.435 |
| Hematogenous metastasis | 4 (250) | 5 (23.8) | 0.933 | 2 (125) | 7 (33.3) | 0.143 |
| Liver | 2 (125) | 5 (23.8) | 0.384 | 0 | 7 (33.3) | 0.010 |
| Lung | 2 (125) | 0 | 0.096 | 2 (125) | 0 | 0.096 |
| Bone | 1 (6.3) | 0 | 0.245 | 0 | 1 (48) | 0.376 |
| Distant lymphatic recurrence | 0 | 3 (14.3) | 0.115 | 0 | 3 (14.3) | 0.115 |
| Virchow’s node | 0 | 0 | 0 | 0 | 1 (3.6) | 0.162 |
| Lymphangitis carcinomatosa | 0 | 0 | 0 | 0 | 2 (3.7) | 0.303 |
| Para-aortic lymph node | 0 | 3 (14.3) | 0.115 | 0 | 3 (14.3) | 0.115 |

| FLI1 hypermethylation | MSC hypermethylation | P value |
|------------------------|-----------------------|---------|
| Without n = 54 | With n = 28 | Without n = 36 | With n = 46 | P value |
| Total recurrence | 22 (40.7) | 16 (57.1) | 0.158 | 16 (44.4) | 22 (47.8) | 0.761 |
| Locoregional recurrence | 11 (204) | 8 (28.6) | 0.404 | 6 (167) | 13 (28.3) | 0.217 |
| Hepatoduodenal ligament | 5 (9.3) | 4 (14.3) | 0.490 | 3 (8.3) | 6 (13.0) | 0.498 |
| Abdominal wall | 6 (11.1) | 5 (17.9) | 0.395 | 3 (8.3) | 8 (17.4) | 0.232 |
| Perigastric area | 1 (19) | 0 | 0.469 | 1 (28) | 0 | 0.255 |
| Anastomosis | 3 (5.6) | 3 (10.7) | 0.395 | 2 (5.6) | 4 (8.7) | 0.588 |
| Distant metastasis | 17 (31.5) | 12 (42.9) | 0.307 | 12 (33.3) | 17 (37.0) | 0.733 |
| Peritoneal dissemination | 9 (16.7) | 3 (10.7) | 0.470 | 6 (167) | 6 (13.0) | 0.645 |
| Hematogenous metastasis | 5 (9.3) | 6 (21.4) | 0.125 | 3 (8.3) | 8 (17.4) | 0.232 |
| Liver | 2 (125) | 0 | 0.096 | 2 (125) | 0 | 0.096 |
| Lung | 2 (125) | 0 | 0.245 | 0 | 1 (48) | 0.376 |
| Bone | 1 (6.3) | 0 | 0.469 | 1 (28) | 0 | 0.255 |
| Distant lymphatic recurrence | 0 | 3 (14.3) | 0.115 | 0 | 3 (14.3) | 0.115 |
| Virchow’s node | 0 | 0 | 0 | 0 | 1 (3.6) | 0.162 |
| Lymphangitis carcinomatosa | 0 | 0 | 0 | 0 | 2 (3.7) | 0.303 |
| Para-aortic lymph node | 0 | 3 (14.3) | 0.115 | 0 | 3 (14.3) | 0.115 |

MSI microsatellite instability, EBV Epstein-Barr virus
In the present study, we demonstrate an approach finding novel hypermethylated genes that can be used to differentiate GC from normal gastric tissue using a genome-wide high-resolution array. We then further validated these genes in tissue and plasma samples. Our novel findings showed that patients with FLI1 hypermethylation in tissue and plasma samples were associated with more advanced GC and more liver and paraaortic lymph node metastases than those without FLI1 hypermethylation. Only for stage III GC, patients with hypermethylation of two or three genes had a worse 5-year DFS rates than those with hypermethylation of one or none of the three genes. FLI1 hypermethylation was an independent prognostic factor affecting OS and DFS in both tissue and plasma samples. Subgroup analysis showed that FLI1 hypermethylation in both tissue and plasma samples was associated with liver metastasis in MSI−/EBV− GC, and MSC hypermethylation in tissue samples was correlated with liver metastasis in MSI+ or EBV+ GC. Patients with FLI1 hypermethylation in plasma samples had a significantly worse 5-year DFS rate than those without FLI1 hypermethylation in MSI−/EBV− GC.

In the present study, we used a genome-wide Illumina methylation EPIC BeadChip assay to identify novel hypermethylated genes that are differentially expressed between GC and normal gastric tissues. The three top hypermethylated genes, ADAM19, FLI1, and MSC, were identified and validated in tissue and plasma samples. In previous reports, FLI1 hypermethylation in tumor tissues was observed in GC [17], colorectal adenomas, and carcinomas [7, 18]. Furthermore, FLI1 hypermethylation was identified in 65.7% of plasma samples obtained from colorectal cancer patients [7]. The above studies indicate that FLI1 hypermethylation could play a tumor suppressor role in both GC and colorectal cancer. Our novel findings show that FLI1 hypermethylation is associated with fewer early GC and more liver and paraaortic lymph node metastases than is observed in those without FLI1 hypermethylation, and these results were consistent across both tissue and plasma samples. To the best of our knowledge, most of the prognostic DNA methylation markers are hypermethylated in MSI+ GC or EBV+ GC, and the methylation status of these markers is likely to be related to the good prognosis. Despite the high incidence of positive methylation in MSI+ or EBV+ GC with good prognosis, it is unlikely that the methylation status of a specific DNA methylation marker is related to the poor prognosis of GC patients. In the subgroup analysis in the present study, although our results showed that FLI1 hypermethylation was significantly more frequent in MSI+ or EBV+ GC than in MSI−/EBV−, FLI1 hypermethylation in plasma was correlated with liver metastasis and a worse 5-year DFS rates. Despite this, the presence of FLI1 hypermethylation in both tissue and plasma samples was associated with liver metastasis in MSI−/EBV− GC, and MSC hypermethylation in tissue samples was correlated with liver metastasis in MSI+ or EBV+ GC. Patients with FLI1 hypermethylation in plasma samples had a significantly worse 5-year DFS rate than those without FLI1 hypermethylation in MSI−/EBV− GC.

### Table 4: The initial recurrence patterns of gastric cancer patients receiving curative surgery with ≥ 2 or < 2 hypermethylated genes in tissue samples according to MSI/EBV status

|                | MSI+ or EBV+ (n = 37) |                  | P value | MSI− and EBV− (n = 82) |                  | P value |
|----------------|------------------------|------------------|---------|------------------------|------------------|---------|
|                | No. of hypermethylated genes | No. of hypermethylated genes |         | No. of hypermethylated genes | No. of hypermethylated genes |         |
|                | < 2 | ≥ 2 | P value | < 2 | ≥ 2 | P value |< 2 | ≥ 2 | P value |
| Total recurrence | 13 (41.9) | 4 (66.7) | 0.266 | 33 (47.8) | 5 (38.5) | 0.535 |
| Locoregional recurrence | 2 (6.5) | 1 (16.7) | 0.401 | 16 (23.2) | 3 (23.1) | 0.993 |
| Hepatoduodenal ligament | 1 (3.2) | 0 | 0.656 | 9 (13.0) | 0 | 0.168 |
| Abdominal wall | 1 (3.2) | 1 (16.7) | 0.183 | 8 (11.6) | 3 (23.1) | 0.265 |
| Perigastric area | 0 | 0 | 0.662 | 1 (1.4) | 0 | 0.662 |
| Anastomosis | 4 (12.9) | 1 (16.7) | 0.805 | 5 (7.2) | 1 (7.7) | 0.955 |
| Distant metastasis | 9 (29.0) | 4 (66.7) | 0.077 | 27 (39.1) | 2 (15.4) | 0.100 |
| Peritoneal dissemination | 2 (6.5) | 2 (33.3) | 0.052 | 12 (17.4) | 0 | 0.104 |
| Hematogenous metastasis | 6 (19.4) | 3 (50.0) | 0.109 | 10 (14.5) | 1 (7.7) | 0.509 |
| Liver | 4 (12.9) | 3 (50.0) | 0.034 | 5 (7.2) | 0 | 0.317 |
| Lung | 2 (6.5) | 0 | 0.522 | 3 (4.3) | 0 | 0.444 |
| Bone | 1 (3.2) | 0 | 0.656 | 4 (5.8) | 1 (7.7) | 0.793 |
| Distant lymphatic recurrence | 2 (6.5) | 1 (16.7) | 0.401 | 9 (13.0) | 1 (7.7) | 0.589 |
| Virchow’s node | 0 | 0 | 0.662 | 1 (1.4) | 0 | 0.662 |
| Lymphangitis carcinomatosa | 0 | 0 | 0.181 | 1 (1.4) | 1 (7.7) | 0.181 |
| Para-aortic lymph node | 2 (6.5) | 1 (16.7) | 0.401 | 8 (11.6) | 0 | 0.196 |

**MSI** microsatellite instability, **EBV** Epstein-Barr virus

**Discussion**

In the present study, we demonstrate an approach finding novel hypermethylated genes that can be used to differentiate GC from normal gastric tissue using a genome-wide high-resolution array. We then further validated these genes in tissue and plasma samples. Our novel findings showed that patients with FLI1 hypermethylation in tissue and plasma samples were associated with more advanced GC and more liver and paraaortic lymph node metastases than those without FLI1 hypermethylation. Only for stage III GC, patients with hypermethylation of two or three genes had a worse 5-year DFS rates than those with hypermethylation of one or none of the three genes. FLI1 hypermethylation was an independent prognostic factor affecting OS and DFS in both tissue and plasma samples. Subgroup analysis showed that FLI1 hypermethylation in both tissue and plasma samples was associated with liver metastasis in MSI−/EBV− GC, and MSC hypermethylation in tissue samples was correlated with liver metastasis in MSI+ or EBV+ GC. Patients with FLI1 hypermethylation in plasma samples had a significantly worse 5-year DFS rate than those without FLI1 hypermethylation in MSI−/EBV− GC.
DFS rate in MSI−/EBV− rather than MSI+ or EBV+ GC, which was another novel finding of the present study. Consequently, FLI1 hypermethylation was associated with GC subtypes, recurrence patterns, and poor prognosis in GC subtypes with MSI−/EBV−. Our results may remind physicians that they should be aware of the possibility of tumor recurrence and poor survival during the surveillance of specific subtypes of GC exhibiting FLI1 hypermethylation.

ADAM19 is a downstream target and a key component of transforming growth factor-beta (TGF-β) signaling. TGF-β can cause growth inhibition in normal ovarian surface

| Table 5 The initial recurrence patterns of gastric cancer patients receiving curative surgery with or without FLI1 hypermethylation in plasma samples according to MSI/EBV status |
|---------------------------------|--|---------------------------------|--|
|                                 | FLI1 hypermethylation | p value | FLI1 hypermethylation | p value |
|                                 | Without n = 10          | With n = 18 | p value | Without n = 41          | With n = 24 | p value |
| Total recurrence                | 6 (60.0)                 | 9 (50.0) | 0.611 | 15 (36.6)                 | 14 (58.3) | 0.089 |
| Locoregional recurrence         | 0                       | 3 (16.7) | 0.172 | 7 (17.1)                  | 7 (29.2) | 0.252 |
| Hepatoduodenal ligament         | 0                       | 1 (5.6)  | 0.448 | 2 (4.9)                   | 3 (12.5) | 0.266 |
| Abdominal wall                  | 0                       | 2 (11.1) | 0.274 | 4 (9.8)                   | 5 (20.8) | 0.212 |
| Perigastric area                | 0                       | 0       | -     | 1 (2.4)                   | 0 | 0.441 |
| Anastomosis                     | 1 (10.0)                 | 4 (22.2) | 0.418 | 3 (7.3)                   | 2 (8.3) | 0.882 |
| Distant metastasis              | 5 (50.0)                 | 6 (33.3) | 0.387 | 11 (26.8)                 | 10 (41.7) | 0.217 |
| Peritoneal dissemination        | 1 (10.0)                 | 2 (11.1) | 0.927 | 7 (17.1)                  | 3 (12.5) | 0.622 |
| Hematogenous metastasis         | 4 (40.0)                 | 3 (16.7) | 0.172 | 2 (4.9)                   | 5 (20.8) | 0.045 |
| Liver                           | 2 (20.0)                 | 3 (16.7) | 0.825 | 0                        | 4 (16.7) | 0.007 |
| Lung                            | 2 (20.0)                 | 0       | 0.119 | 2 (4.9)                   | 0 | 0.272 |
| Bone                            | 1 (10.0)                 | 0       | 0.172 | 2 (4.9)                   | 1 (4.2) | 0.895 |
| Distant lymphatic recurrence    | 0                       | 2 (11.1) | 0.274 | 3 (7.3)                   | 5 (20.8) | 0.109 |
| Virchow's node                  | 0                       | 0       | -     | 0                        | 1 (4.2) | 0.188 |
| Lymphangitis carcinomatosa      | 0                       | 0       | -     | 2 (4.9)                   | 0 | 0.272 |
| Para-aortic lymph node          | 0                       | 2 (11.1) | 0.274 | 1 (2.4)                   | 5 (20.8) | 0.013 |

MSI microsatellite instability, EBV Epstein-Barr virus
epithelial cells, induce the nuclear translocation of SMAD4, and upregulate ADMA19. In ovarian cancer cells, the induction and nuclear translocation of SMAD4 were negligible and refractory to TGF-β1 stimulation, the promoter region of ADAM19 was hypermethylated, and ADAM19 expression was greatly reduced. These results suggest that ADAM19 hypermethylation may contribute to ovarian cancer [19]. The novel findings in the present study demonstrated that patients with ADAM19 hypermethylation more often exhibited stage IV GC than those without ADAM19 hypermethylation in both tissue and plasma samples. Consequently, ADAM19 hypermethylation indicates a high possibility of stage IV GC, which can provide an important gauge for physicians and might influence subsequent treatment modalities.

MSC hypermethylation was reported to be strongly associated with increasing disease severity in the histological progression from gastritis with no metaplasia, to gastritis with metaplasia, to gastric adenocarcinoma [20]. Our results showed that GC patients with MSC hypermethylation in plasma had, based on gross morphology, more non-superficial type tumors than were found in those without MSC hypermethylation. Patients with non-superficial-type gastric tumors and MSC hypermethylation in plasma might therefore have a high risk of GC. As a result, patients highly suspected of having GC by endoscopists but apparently lacking malignancy based on the pathology of a biopsied specimen could benefit from a test to identify MSC hypermethylation in plasma. In the subgroup analysis, patients with MSC hypermethylation were associated with more liver metastasis in MSI+ or EBV+ GC, rather than MSI−/EBV− GC, which is another novel finding of the present study. Consequently, our results might remind physicians to be aware of liver metastasis during follow-up for MSI+ or EBV+ GC exhibiting MSC hypermethylation.

With the combination of the three hypermethylated genes, our results demonstrated that in both tissue and plasma samples, patients with hypermethylation of all three genes had significantly more liver metastases and more paraaortic lymph node metastases than patients with hypermethylation of one, two, or none of the three genes. Moreover, especially in stage III GC, the 5-year DFS rates were significantly worse in patients with two or three hypermethylated genes than in those with one or no hypermethylated genes. Consequently, the three hypermethylated genes could serve as useful biomarkers for predicting tumor recurrence patterns and patient survival in GC patients. We hope that our methods for identifying hypermethylated markers with clinical significance can be applied for not only GC but also for other types of cancer in the future.

DNA methylation profiles at the precancerous stage may indicate tumor aggressiveness and patient survival for various cancers, including GC [21–26]. As a result, the accumulation of DNA methylation of multiple tumor-associated genes may result in carcinogenesis from the precancerous stage to cancer and even tumor progression. The investigation of DNA methylation of tumor-related genes can be helpful in early cancer detection, early detection of tumor progression, and prediction of patient prognoses. Because methylation studies are not easy to perform in the routine practice, the results of immunohistochemical staining for the three genes may be associated with the methylation status and could be used in the clinical practice, follow-up, and therapy modification for GC patients.

There are some limitations to the present study. First, this is a retrospective study, and bias could exist. Second, although our results showed that FLI1 hypermethylation was significantly associated with recurrence patterns in GC, and stage III GC patients with two or three hypermethylated genes had worse 5-year DFS rates than those with one or no hypermethylated genes, the number of patients was limited, and bias might have occurred. In the future, we will enroll more patients, and further in vivo and in vitro studies should be performed to validate these findings. Third, we did not validate the status of the top three hypomethylated genes, including TACSTD2, SIM2, and DAPK, in tissue and plasma samples in the present study. Our future study will focus on the hypomethylation status of the three genes and their clinical relevance in tissue and plasma samples will be investigated as well.

### Table 6 The summary of the prognostic value of patients with hypermethylated genes compared with those without hypermethylated genes in tissue and plasma samples

| Clinicopathological features | ADAM19 methylation | FLI1 methylation | MSC methylation |
|-----------------------------|--------------------|-----------------|-----------------|
| Tissue                      | Plasma             | Tissue          | Plasma          |
| Initial recurrence pattern  | No correlation     | No correlation  | No correlation  |
| Patient prognosis           | No correlation     | Independent prognostic factor of OS and DFS | No correlation |

| DFS disease-free survival, GC gastric cancer, LN lymph node, OS overall survival | 
|-----------------------------------------------|

ADAM19 methylation was associated with more liver metastasis in MSI+ or EBV+ GC, which is another novel finding of the present study. Consequently, our results might remind physicians to be aware of liver metastasis during follow-up for MSI+ or EBV+ GC exhibiting MSC hypermethylation. With the combination of the three hypermethylated genes, our results demonstrated that in both tissue and plasma samples, patients with hypermethylation of all three genes had significantly more liver metastases and more paraaortic lymph node metastases than patients with hypermethylation of one, two, or none of the three genes. Moreover, especially in stage III GC, the 5-year DFS rates were significantly worse in patients with two or three hypermethylated genes than in those with one or no hypermethylated genes. Consequently, the three hypermethylated genes could serve as useful biomarkers for predicting tumor recurrence patterns and patient survival in GC patients. We hope that our methods for identifying hypermethylated markers with clinical significance can be applied for not only GC but also for other types of cancer in the future.

DNA methylation profiles at the precancerous stage may indicate tumor aggressiveness and patient survival for various cancers, including GC [21–26]. As a result, the accumulation of DNA methylation of multiple tumor-associated genes may result in carcinogenesis from the precancerous stage to cancer and even tumor progression. The investigation of DNA methylation of tumor-related genes can be helpful in early cancer detection, early detection of tumor progression, and prediction of patient prognoses. Because methylation studies are not easy to perform in the routine practice, the results of immunohistochemical staining for the three genes may be associated with the methylation status and could be used in the clinical practice, follow-up, and therapy modification for GC patients.

There are some limitations to the present study. First, this is a retrospective study, and bias could exist. Second, although our results showed that FLI1 hypermethylation was significantly associated with recurrence patterns in GC, and stage III GC patients with two or three hypermethylated genes had worse 5-year DFS rates than those with one or no hypermethylated genes, the number of patients was limited, and bias might have occurred. In the future, we will enroll more patients, and further in vivo and in vitro studies should be performed to validate these findings. Third, we did not validate the status of the top three hypomethylated genes, including TACSTD2, SIM2, and DAPK, in tissue and plasma samples in the present study. Our future study will focus on the hypomethylation status of the three genes and their clinical relevance in tissue and plasma samples will be investigated as well.
Conclusions
Our results showed that a genome-wide high-resolution array analysis may be useful for investigating novel hypermethylated genes, which can be further validated in tissue and plasma samples. DNA methylation can serve as a useful biomarker for predicting recurrence patterns and survival in both GC patients and GC subtypes. The present study demonstrated the potential clinical utility of identifying the DNA methylation status in both tissue and plasma in GCs and broader application might be achieved in other tumor types.

Materials and methods
Study design
The study design is shown in Fig. 5. A total of 157 GC patients were enrolled in this study. A genome-wide methylation profiling was performed using an Illumina Methylation EPIC BeadChip assay in a discovery set of 16 GC patients, including four patients in each TNM stage. The top three hypermethylated genes at CpG sites that were differentially expressed between tumor and normal gastric tissues were selected as candidate genes. Validation of the same methylated CpG sites of the three genes as identified from the EPIC arrays was performed for tumor and normal gastric tissues in 141 GC patients (excluding the discovery set of 16 GC patients) using MassARRAY-based methylation profiling, and we further investigated the correlations between the clinicopathological characteristics and the methylation status of the three genes in all 141 patients. Validation of the same CpG sites of the three genes was additionally performed using next-generation sequencing (NGS) analysis in 106 patients for whom plasma samples prior to surgery were available. The plasma samples of 20 healthy individuals were used as the control samples. The relationships between the clinicopathological characteristics and expression profiles of the top three hypermethylated genes were investigated. Furthermore, we also performed analyses of MSI and EBV status for GC tissue samples, and GC patients were divided into subtypes according to MSI/EBV status. The methylation frequencies of the three genes and the initial recurrence patterns were compared among the GC subtypes.

Patient selection and surgical treatment
Between April 2005 and December 2011, a total of 157 GC patients who underwent surgery for GC were enrolled in this study. Informed written consent was obtained from all enrolled patients, and this study was approved by the Institutional Review Board at our institute.

Pathological staging of GC was performed according to the eighth American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) TNM classification [27]. All operations were performed by surgeons who specialized in GC. The data were prospectively collected and recorded using a computer, and the patients’ follow-up conditions were regularly updated.

Follow-up
Overall survival was calculated from the time of surgery until death or the date of the last follow-up. None of the patients received preoperative chemotherapy. Before 2008, neither adjuvant chemotherapy nor radiotherapy was routinely performed after curative surgery; rather, these procedures were performed only when tumor recurrence was diagnosed or highly suspected. Since 2008, adjuvant therapy (such as TS-1) has been prescribed for stage II or stage III patients who underwent curative surgery in our hospital. Among the 141 patients (validation set), 119 patients received curative surgery, including 95 patients who were stage II or stage III. Sixteen out of the 95 patients received postoperative adjuvant chemotherapy, including TS-1 for one patient and 5-FU-based intravenous chemotherapy for 15 patients. Among the total 141 patients enrolled in the present study, two patients received surgery after 2008, including one stage II and one stage III GC; the stage III GC patient was the only one patient receiving TS-1 therapy.

Follow-up assessments were performed every 3 months for the first 5 years after surgery and every 6 months thereafter until the patient’s death. The follow-up procedures included medical histories, physical examinations, routine blood tests, liver function tests, measurements of tumor marker levels (carcinoembryonic antigen and carbohydrate antigen 19-9), chest radiography, abdominal sonography, or CT scan.

DNA extraction
DNA was extracted from tissue specimens and 800 ul of plasma using the QIAamp DNA Tissue Kit and MinElute Virus Kit (Qiagen, Valencia, CA, USA), respectively, according to the manufacturer’s recommendations. For plasma isolation, whole blood was centrifuged at 2600 rpm for 10 min at 10 °C. The collected material was centrifuged once again in 2-ml low-bind tubes at 14,500 rpm for 10 min to remove residual cells. All samples were stored at −20 °C until cfDNA isolation. DNA quality and quantity were confirmed using a NanoDrop 1000 Spectrophotometer (Thermo Scientific) and Qubit Fluorometer (Thermo Scientific), respectively.
**MSI analysis**

As mentioned in a previous study [28], the DNA of normal and tumor tissues was extracted, purified, and then amplified using a fluorescent PCR. Five reference microsatellite markers (D5S345, D2S123, D17S250, BAT25, and BAT26) were used for the analysis of microsatellite instability (MSI). MSI+ was defined when samples had ≥2 loci of instability with five markers. MSI− was defined as samples with one MSI or without MSI.
EBV DNA detection based on MassARRAY
As reported in a previous study [29], EBV DNA assays were carried out using the MassARRAY system (Agenda, San Diego, CA, USA). The PCR and single-base extension primers were designed using the MassARRAY Assay Design 3.1 software, and one multiplex reaction was designed to detect the EBV virus DNA segment.

Genome-wide methylation analysis
A total of 600 ng of genomic DNA was obtained from the tumors and adjacent non-tumor tissues of 16 GC patients (four in each TNM stage) and subjected to epigenotyping using a genome-wide Illumina methylation EPIC BeadChip kit according to the manufacturer’s instructions. After bisulfate conversion, two criteria were required in the subsequent Illumina methylation beadarray: ssDNA concentration > 10 ng/μl using a Quant-iT ssDNA assay kit (Thermo Fisher) and positive PCR results for cg05524038 or cg27640254. Then, whole-genome amplification, enzymatic fragmentation, precipitation, resuspension, and hybridization were performed, and the intensity data were acquired using an Illumina HiScan scanner. The resulting image was processed using the GenomeStudio Methylation module (Illumina) to obtain the β value for each CpG site [4]. Hypomethylation was defined as a DiffScore ≤ −0.2, while hypermethylation was defined as a DiffScore ≥ 30 and a delta β value > 0.2 [4, 30].

MassARRAY-based methylation profiling
The top three hypermethylated genes were ADAM19, FLI1, and MSC, and methylation profiling was performed in these three genes using a MassARRAY EpiTYPER (Agena Bioscience, San Diego, CA, USA) based on MassCLEAVE base-specific cleavage and matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry. Primers were designed using the Epidesigner online software, and the quantitative methylation data for each CpG site or aggregates of multiple CpG sites were obtained from MassARRAY and analyzed using EpiTYPER software (Agena Bioscience, San Diego, CA, USA). MassARRAY and NGS were used to quantify methylation states. Tumor and adjacent normal tissues were both used to perform methylation profiling, and the average methylation value of CpG sites was used to measure methylation. If the methylation value was more than the mean + 2SD of the normal control group, the case was defined as hypermethylation.

NGS-based target gene methylation sequencing
To detect the methylation status of candidate CpG sites of interest in cell-free DNA (cfDNA) extracted from plasma samples prior to surgery, amplicon-based enrichments for Illumina NGS sequencers were used to obtain a higher sensitivity. EpiTect Control DNA (Qiagen) was used to evaluate the performance of the target methylation sequencing design. The values of all target methylation sites were 0.98 ± 0.05 and 0.01 ± 0.02 in methylated and unmethylated controls, respectively, indicating the quantification abilities of the primer and read data were acceptable for this study. Bisulfite-converted cfDNA (10 ng) was obtained from each individual and used to amplify target CpG regions (amplicon sizes, 80–120 bp). Then, the amplicons of each sample were pooled after Ampure XP bead-based PCR purification (Beckman) and Qubit-based quantification (Thermo Fisher). The pooled amplicons were used to construct a sample library with a Roche KAPA Library Preparation Kit (Roche). The amplified libraries were quantified using a qPCR system and pooled into a single 1.5-ml tube to obtain a 10-nM pooled DNA library. The final pool was used for sequencing (Illumina MiniSeq sequencer, 2 × 150 bp). The raw output for each individual patient was 20 Mb, and the average depth of the target regions was >1000×. In addition to cancer patients, the cfDNA of 20 healthy individuals (normal control group) was also used to perform target methylation sequencing using the above method. Finally, we directly evaluated the methylation status by analyzing read sequence-identified variants, and CpG sites for which the average methylation percentage of the target was larger than the mean + 2SD of that in the control group were considered hypermethylated phenotypes and included in the statistical analysis.

Statistical analysis
Statistical analyses were performed using IBM SPSS version 24.0. Categorical data were compared using a χ² test with Yates’ correction or Fisher’s exact test. The overall survival (OS) was measured from the operation date to the date of death or the final follow-up. Disease-free survival (DFS) was defined as the length of time after GC surgery during which a patient survived without tumor recurrence. The distributions of OS and DFS were estimated using the Kaplan-Meier method. Multivariate analysis using Cox proportional hazards models was performed to explore the association of the clinical parameters with OS and DFS. A P value of <0.05 was considered to be statistically significant.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13148-019-0747-5.

Additional file 1: The raw data of the results of genome-wide methylation profiling using an Illumina Methylation EPIC BeadChip assay.
Additional file 2: The data of the hypermethylated and hypomethylated genes that were differentially expressed between the normal and tumor tissues in the discovery set of 16 GC patients.
Additional file 3: The raw data of the clinical profile of the discovery set of 16 GC patients.
Competing interests
Not applicable

Consent for publication
Declaration of Helsinki. Written informed consent was obtained from all patients. The investigation was approved by the Ethical Committee of Taipei Veterans Taiwan11217. 4Division of Colon & Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei City, Taiwan11217. 5Department of Oncology, Taipei Veterans General Hospital, Taipei City, Taiwan11217. 6Division of Colon & Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei City, Taiwan11217. 7Department of Pathology, Taipei Veterans General Hospital, Taipei City 11217, Taiwan.

Received: 1 May 2019 Accepted: 22 September 2019
Published online: 01 November 2019

Abbreviations
ADAM19: A Disintegrin and Metalloproteinase 19; AJCC: American Joint Committee on Cancer; CT: Computed tomography; DFS: Disease-free survival; EBV: Epstein-Barr virus; FLI1: Friend Leukemia Integration 1; GC: Gastric cancer; HP: Helicobacter pylori; MALDI-TOF: Matrix-assisted laser desorption ionization-time of flight; MSC: Musculin; MSI: Microsatellite instability; MSI+: Microsatellite instability-high; NGS: Next-generation sequencing; OS: Overall survival; PCR: Polymerase chain reaction; TCGA: The Cancer Genome Atlas; TGF-β: Transforming growth factor-beta; UICC: Union for International Cancer Control

Acknowledgements
We thank Dr. Chien-Hsing Lin for the technical support in NGS sequencing and MassARRAY analysis and Ms. Ling-Chen Tai for the support of data analysis.

Authors’ contributions
WLF and KHH conducted patient enrolment and clinical work. CHL performed a genome-wide methylation analysis, MassARRAY-based methylation profiling, and NGS-based target gene methylation sequencing experiments. WLF performed statistical analyses and wrote the manuscript. All authors have revised and approved the manuscript.

Funding
This research was supported by the Ministry of Science and Technology, Taiwan (grant number: 105-2628-B-075-004-MY2). None of the sources of funding played a role in the study design, data collection, the analysis and interpretation of the data, the writing of the manuscript, or the decision to submit the manuscript for publication.

Availability of data and materials
The datasets generated and/or analyzed during the current study are available for non-commercial use from the corresponding author on reasonable request.

Ethics approval and consent to participate
The investigation was approved by the Ethical Committee of Taipei Veterans General Hospital. The study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all study participants.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, No. 201, Sec. 2, Shihai Rd, Beitou District, Taipei City, Taiwan11217. 2School of Medicine, National Yang-Ming University, Taipei City, Taiwan11217. 3Department of Oncology, Taipei Veterans General Hospital, Taipei City, Taiwan11217. 4Division of Colon & Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei City, Taiwan11217. 5Department of Pathology, Taipei Veterans General Hospital, Taipei City, Taiwan11217. 6Division of Colon & Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei City, Taiwan11217. 7Genome Research Center, National Yang-Ming University, Taipei City, Taiwan11217.

References
1. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–53.
2. Chong Y, Mia-Jan K, Ryu H, et al. DNA methylation status of a distinctively different subset of genes is associated with each histologic Lauren classification subtype in early gastric carcinogenesis. Oncol Rep. 2014;31:2535–44.
3. Que N, Mitani Y, Motoshita J, et al. Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer. 2006;106:1250–9.
4. Kibiya MG, Raza M, Jasmine F, et al. A genome-wide DNA methylation study in colorectal carcinoma. BMC Med Genet. 2011;4:50.
5. Sarapi NS, Loh M, Vaithilingam A, Soong R. Clinical potential of DNA methylation in gastric cancer: a meta-analysis. PLoS One. 2012;7:e36275.
6. Kiessl B, Duquek BA, Kanipakam RVSr, et al. Hepatocellular carcinoma detection by plasma methylated DNA: discovery, phase I pilot, and phase II clinical validation. Hepatology. 2018;31 [Epub ahead of print].
7. Lin PC, Lin JK, Lin CH, et al. Clinical relevance of plasma DNA methylation in colorectal cancer patients identified by using a genome-wide high-resolution array. Ann Surg Oncol. 2015;22:Suppl 3:S1419–27.
8. Anderson BW, Suh YS, Choi B, et al. Detection of gastric cancer with novel methylated DNA markers: discovery, tissue validation and pilot testing in plasma. Clin Cancer Res. 2018;24:5724–34.
9. TCGA. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;451:202–9.
10. Cristesci R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449–56.
11. Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shin JJ, Lee KW, Kim EH, Yim SY, Lee SH, et al. Clinical significance of four molecular subtypes of gastric cancer identified by The Cancer Genome Atlas Project. Clin Cancer Res. 2017. [Epub ahead of print]
12. Wu L, Zhang C, Wang X, Ding X, Deng J, Liang H. Methylation of ASC/TMS1 promoter is associated with poor prognosis of patients with gastric cancer. Clin Transl Oncol. 2016;18:296–303.
13. Zhang Z, Yu W, Chen S, Chen Y, Chen L, Zhang S. Methylation of the claudin-3 promoter predicts the prognosis of advanced gastric adenocarcinoma. Oncol Rep. 2018;40:49–60.
14. Sui BQ, Zhang CD, Liu JC, Wang L, Dai DQ, HOX813 expression and promoter methylation as a candidate biomarker in gastric cancer. Oncol Lett. 2018;15:8833–40.
15. Guo YL, Zhu TN, Guo W, Dong ZM, Zhou Z, Cui YJ, Zhao RJ. Aberrant CpG island shore region methylation of CAV1 is associated with tumor progression and poor prognosis in gastric cardia adenocarcinoma. Arch Med Res. 2016;47:460–70.
16. Wang N, Sui F, Li J, Xu X, Liu J, Yao D, Shi B, Hou P, Yang Q. Site-specific hypermethylation of RUNX3 predicts poor prognosis in gastric cancer. Arch Med Res. 2016;47:285–92.
17. Sepulveda JL, Gutierrez-Pajares JL, Luna A, et al. High-definition CpG methylation of novel genes in gastric carcinogenesis identified by next-generation sequencing. Mod Pathol. 2016;29:182–93.
18. Oster B, Thorsen K, Lamy P, et al. Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. Int J Cancer. 2011;129:2855–66.
19. Chan MW, Haung YW, Hartman-Frey C, et al. Aberrant transforming growth factor beta 1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia. 2008;10:908–19.
20. Pirini F, Noazin S, Jahn-Jarvis MM, et al. Early detection of gastric cancer using global, genome-wide and IRF4, ELMO1, CLIP4 and MEC DNA methylation in endoscopic biopsies. Oncotarget. 2017;8:38501–16.
21. Sato T, Arai E, Kohno T, et al. DNA methylation profiles at pre-cancerous stages associated with recurrence of lung adenocarcinoma. PLoS One. 2013; 8:e59444.
22. Arai E, Ushijima S, Fujimoto H, et al. Genome-wide DNA methylation profiles in both precancerous conditions and clear cell renal cell carcinomas are correlated with malignant potential and patient outcome. Carcinogenesis. 2009;30:214–21.

23. Nishiyama N, Arai E, Chihara Y, et al. Genome-wide DNA methylation profiles in urothelial carcinomas and urothelia at the precancerous stage. Cancer Sci. 2010;101:231–40.

24. Nagashio R, Arai E, Ojima H, Kosuge T, Kondo Y, Kanai Y. Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage. Int J Cancer. 2011;129:1170–9.

25. Peng DF, Kanai Y, Sawada M, et al. DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis. 2006;27:1160–8.

26. Yamanoi K, Arai E, Tian Y, et al. Epigenetic clustering of gastric carcinomas based on DNA methylation profiles at the precancerous stage: its correlation with tumor aggressiveness and patient outcome. Carcinogenesis. 2015;36:509–20.

27. Amin MB, Edge S, Greene F, et al. AJCC cancer staging manual. 8th ed. Chicago: Springer; 2017.

28. Fang WL, Chang SC, Lan YT, et al. Microsatellite instability is associated with a better prognosis for gastric cancer patients after curative surgery. World J Surg. 2012;36:2131–8.

29. Fang WL, Huang KH, Chang SC, et al. Comparison of the clinicopathological characteristics and genetic alterations between patients with gastric cancer with or without Helicobacter pylori infection. Oncologist. 2019;24:e845-e853.

30. Sandoval J, Heyn H, Moran S, et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics. 2011;6:692–702.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.